Catheter Precision, Inc. Announces New Clinical Data Presented at SCRN
Catheter Precision (NYSE American:VTAK) presented new clinical data from the VIVO EU Registry at the Society of Cardiac Robotic Navigation meeting in Lisbon. Professor Leonor Parreira shared final data from Hospital da Luz, involving 27 subjects, of which 18 underwent ablation procedures. The results showed 100% accurate identification of site origin, approximately 95% successful ablation procedures, and 83% of patients remained arrhythmia-free at 12 months post-ablation. The company plans to publish complete study results including data from seven additional studies.
Catheter Precision (NYSE American:VTAK) ha presentato nuovi dati clinici dal Registro VIVO EU durante il meeting della Society of Cardiac Robotic Navigation a Lisbona. La Professoressa Leonor Parreira ha condiviso i dati finali dell'Hospital da Luz, che coinvolgevano 27 soggetti, dei quali 18 hanno subito procedure di ablazione. I risultati hanno mostrato un'identificazione 100% accurata del sito di origine, circa 95% di procedure di ablazione riuscite, e 83% dei pazienti sono rimasti senza aritmie a 12 mesi dopo l'ablazione. L'azienda prevede di pubblicare i risultati completi dello studio, inclusi i dati di sette ulteriori studi.
Catheter Precision (NYSE American:VTAK) presentó nuevos datos clínicos del Registro VIVO EU en la reunión de la Society of Cardiac Robotic Navigation en Lisboa. La Profesora Leonor Parreira compartió los datos finales del Hospital da Luz, que involucraron a 27 sujetos, de los cuales 18 se sometieron a procedimientos de ablación. Los resultados mostraron una identificación 100% precisa del sitio de origen, aproximadamente 95% de procedimientos de ablación exitosos y 83% de los pacientes permanecieron sin arritmias a los 12 meses después de la ablación. La empresa planea publicar los resultados completos del estudio, incluidos los datos de otros siete estudios.
Catheter Precision (NYSE American:VTAK)는 리스본에서 열린 심장 로봇 내비게이션 학회에서 VIVO EU 레지스트리의 새로운 임상 데이터를 발표했습니다. 레오노르 파레이라 교수는 Hospital da Luz의 최종 데이터를 공유했으며, 27명의 대상자가 포함되었고, 그 중 18명이 절제 절차를 받았습니다. 결과는 원점의 100% 정확한 식별, 약 95%의 성공적인 절제 절차, 그리고 83%의 환자가 절제 후 12개월 동안 부정맥이 없는 상태를 유지한 것을 보여주었습니다. 회사는 7개의 추가 연구 데이터를 포함한 전체 연구 결과를 발표할 계획입니다.
Catheter Precision (NYSE American:VTAK) a présenté de nouvelles données cliniques du registre VIVO EU lors de la réunion de la Society of Cardiac Robotic Navigation à Lisbonne. La Professeure Leonor Parreira a partagé les données finales de l'Hospital da Luz, impliquant 27 sujets, dont 18 ont subi des procédures d'ablation. Les résultats ont montré une identification 100% précise du site d'origine, environ 95% de procédures d'ablation réussies et 83% des patients sont restés sans arythmie 12 mois après l'ablation. L'entreprise prévoit de publier les résultats complets de l'étude, y compris les données de sept études supplémentaires.
Catheter Precision (NYSE American:VTAK) präsentierte neue klinische Daten aus dem VIVO EU Register auf dem Meeting der Society of Cardiac Robotic Navigation in Lissabon. Professorin Leonor Parreira teilte die endgültigen Daten des Hospital da Luz, die 27 Probanden umfassten, von denen 18 Ablationsverfahren unterzogen wurden. Die Ergebnisse zeigten eine 100% genaue Identifizierung des Ursprungsortes, etwa 95% erfolgreiche Ablationsverfahren und 83% der Patienten blieben 12 Monate nach der Ablation frei von Arrhythmien. Das Unternehmen plant, die vollständigen Studienergebnisse, einschließlich Daten von sieben zusätzlichen Studien, zu veröffentlichen.
- 100% accuracy in identifying cardiac segment origin
- 95% success rate in ablation procedures
- 83% of patients remained arrhythmia-free after 12 months
- First study with 12-month post-ablation follow-up data
- None.
Insights
The clinical data from the VIVO EU Registry demonstrates significant medical efficacy with impressive metrics:
The study's sample size of 27 subjects, while modest, provides valuable initial validation of VIVO's clinical utility. The long-term follow-up data at 12 months is a important differentiator, as it helps establish the durability of the treatment effect. This could position VTAK's technology as a valuable tool in cardiac electrophysiology, potentially leading to broader adoption and market penetration in the cardiac mapping and ablation space.
FORT MILL, SC / ACCESSWIRE / November 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced that new clinical data from the VIVO EU Registry was presented last week at the Society of Cardiac Robotic Navigation (SCRN) meeting in Lisbon, Portugal.
As previously announced, there were three presentations about VIVO during the SCRN meeting which took place October 28-29. The presentation by Professor Leonor Parreira shared the final data from Hospital da Luz. This center enrolled 27 subjects of which 18 proceeded with an ablation procedure with the following results:
100% accurate identification of the site of origin to the exact or neighboring cardiac segment17 (≈
95% ) patients had successful ablation procedures83% of patients had no recurrence of the arrhythmia at 12 months post ablation
"
About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
At the Company
David Jenkins
973-691-2000
IR@catheterprecision.com
# # #
Contact Information
Missiaen Huck
COO
mhuck@catheterprecision.com
9736912000
SOURCE: Catheter Precision, Inc.
View the original press release on accesswire.com
FAQ
What were the success rates of VTAK's VIVO system in the Hospital da Luz study?
How many patients were included in VTAK's Hospital da Luz VIVO study?
When and where was the new VTAK VIVO clinical data presented?
What is the significance of VTAK's latest VIVO study results?
